Abl tyrosine kinase in signal transduction and cell-cycle regulation.
暂无分享,去创建一个
[1] Bruce A. Roe,et al. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene , 1986, Cell.
[2] J. Wang,et al. Differential expression of type-specific c-abl mRNAs in mouse tissues and cell lines , 1988, Molecular and cellular biology.
[3] D. Baltimore,et al. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo , 1992, Molecular and cellular biology.
[4] D. Baltimore,et al. Identification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho. , 1992, Science.
[5] J. Wang,et al. Oncogenic v‐Abl tyrosine kinase can inhibit or stimulate growth, depending on the cell context. , 1992, The EMBO journal.
[6] T. Hunter,et al. A 41-kilodalton protein is a potential substrate for the p210bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells , 1992, Molecular and cellular biology.
[7] G. Daley,et al. Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line , 1992, Molecular and cellular biology.
[8] O. Witte,et al. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias , 1991, Molecular and cellular biology.
[9] Joseph Schlessinger,et al. Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.
[10] R. Bronson,et al. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene , 1991, Cell.
[11] S. Moreno,et al. Substrates for p34 cdc2 : In vivo veritas? , 1990, Cell.
[12] G. Daley,et al. Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome-positive human leukemia. , 1991, Advances in cancer research.
[13] J. Wang. Oncoprotein phosphorylation and cell cycle control. , 1992, Biochimica et biophysica acta.
[14] Rosalind C. Lee,et al. The mouse c-abl locus: Molecular cloning and characterization , 1984, Cell.
[15] F. Hoffmann,et al. DNA sequence, structure, and tyrosine kinase activity of the Drosophila melanogaster Abelson proto-oncogene homolog , 1988, Molecular and cellular biology.
[16] J. Wang,et al. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins , 1991, Molecular and cellular biology.
[17] P. O’Farrell,et al. Progression of the cell cycle through mitosis leads to abortion of nascent transcripts , 1991, Cell.
[18] F. McCormick,et al. Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[19] D. Baltimore,et al. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization , 1989, Cell.
[20] Jean Y. J. Wang,et al. Cell Cycle—Regulated Binding of c-Abl Tyrosine Kinase to DNA , 1992, Science.
[21] G. Kruh,et al. Arg encodes a widely expressed 145 kDa protein-tyrosine kinase. , 1991, Oncogene.
[22] O. Witte,et al. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner , 1991, Cell.
[23] P. Nurse,et al. Animal cell cycles and their control. , 1992, Annual review of biochemistry.
[24] W. Kaelin,et al. Identification of a growth suppression domain within the retinoblastoma gene product. , 1992, Genes & development.
[25] S. Goff,et al. Mice homozygous for the abl m1 mutation show poor viability and depletion of selected B and T cell populations , 1991, Cell.
[26] F. Hoffmann,et al. A novel tyrosine kinase-independent function of Drosophila abl correlates with proper subcellular localization , 1990, Cell.
[27] R. Reeves. Chromatin changes during the cell cycle. , 1992, Current opinion in cell biology.
[28] D. Baltimore,et al. N‐terminal mutations activate the leukemogenic potential of the myristoylated form of c‐abl. , 1989, The EMBO journal.
[29] P. Bergold,et al. Structure and origins of the HZ2-feline sarcoma virus. , 1987, Virology.
[30] N. Rosenberg,et al. Lymphoid cells transformed by Abelson virus require the v-abl protein-tyrosine kinase only during early G1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[31] G. Daley,et al. Alternative 5′ exons in c-abl mRNA , 1986, Cell.
[32] S. Aaronson,et al. The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[33] J. Wang,et al. Deletion of an N‐terminal regulatory domain of the c‐abl tyrosine kinase activates its oncogenic potential. , 1989, The EMBO journal.
[34] N. Rosenberg,et al. The viral and cellular forms of the Abelson (abl) oncogene. , 1988, Advances in virus research.
[35] W. Jy,et al. Reversible dependence on growth factor interleukin-3 in myeloid cells expressing temperature sensitive v-abl oncogene. , 1988 .
[36] Y. Shaul,et al. c-abl has a sequence-specific enhancer binding activity , 1992, Cell.
[37] J. Wang,et al. Differential phosphorylation of c-Abl in cell cycle determined by cdc2 kinase and phosphatase activity. , 1990, Science.
[38] T Pawson,et al. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. , 1991, Science.
[39] Hoffman Fm. Drosophila abl and genetic redundancy in signal transduction , 1991 .
[40] J. Bolen. Signal transduction by the SRC family of tyrosine protein kinases in hemopoietic cells. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.